Lucio Boglione

Prof. Lucio Boglione

Infectious Diseases Unit, University of Eastern Piedmont, Novara, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
Lucio BoglioneLucio Boglione
Lucio Boglione
GMG Meli
G Meli
FPF Poletti
F Poletti
RRR Rostagno
R Rostagno
RMR Moglia
R Moglia
SBS Borrè
S Borrè
The definition of ‘long-COVID syndrome’ (LCS) is still debated and describes the persistence of symptoms after viral clearance in hospitalized or non-hospitalized patients affected by coronavirus disease 2019 (COVID-19). In this study, we examined the prevalence and the risk factors of LCS in a cohort of patients with previous COVID-19 and followed for at least 6 months of follow-up. We conducted a prospective study including all hospitalized patients affected by COVID-19 at our center of Infectious Diseases (Vercelli, Italy) admitted between 10 March 2020 and 15 January 2021 for at least 6 months after discharge. Two follow-up visits were performed: after 1 and 6 months after hospital discharge. Clinical, laboratory and radiological data were recorded at each visit. A total of 449 patients were included in the analysis. The LCS was diagnosed in 322 subjects at Visit 1 (71.7%) and in 206 at Visit 2 (45.9); according to the post-COVID-19 functional status scale we observed 147 patients with values 2–3 and 175 with values >3 at Visit 1; at Visit 2, 133 subjects had the score between 2–3 and 73 > 3. In multivariate analysis, intensive care unit (ICU) admission (OR = 2.551; 95% CI = 1.998–6.819; P = 0.019), time of hospitalization (OR = 2.255; 95% CI = 1.018–6.992; P = 0.016) and treatment with remdesivir (OR = 0.641; 95% CI = 0.413–0.782; P < 0.001) were independent predictors of LCS. Treatment with remdesivir leads to a 35.9% reduction in LCS rate in follow-up. Severity of illness, need of ICU admission and length of hospital stay were factor associated with the persistence of PCS at 6 months of follow-up.

8 February 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
TLTommaso Lupia
Tommaso Lupia
CPCarlo Pallotto
Carlo Pallotto
Silvia CorcioneSilvia Corcione
Silvia Corcione
Lucio BoglioneLucio Boglione
Lucio Boglione
FRFrancesco Giuseppe De Rosa
Francesco Giuseppe De Rosa
Ceftobiprole combines an excellent spectrum for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) pathogens, with a low/medium MDR risk, and the β-lactams’ safety in frail patients admitted to the hospital in internal medicine wards which may be at high risk of adverse events by anti-MRSA coverage as oxazolidinones or glycopeptides. We aimed to report the available evidence regarding ceftobiprole use in pneumonia and invasive bacterial infections, shedding light on ceftobiprole stewardship. The clinical application and real-life experiences of using ceftobiprole for bloodstream infections, including infective endocarditis, are limited but nevertheless promising. In addition, extended-spectrum ceftobiprole activity, including Enterococcus faecalis, Enterobacteriaceae, and Pseudomonas aeruginosa, has theoretical advantages for use as empirical therapy in bacteremia potentially caused by a broad spectrum of microorganisms, such as catheter-related bacteremia. In the future, the desirable approach to sepsis and severe infections will be administered to patients according to their clinical situation, the intrinsic host characteristics, the susceptibility profile, and local epidemiology, while the “universal antibiotic strategy” will no longer be adequate.

13 May 2021 in Disease Markers
Verified
Journal Article
Open access
PDF file
MBMattia Bellan
Mattia Bellan
DADanila Azzolina
Danila Azzolina
EHEyal Hayden
Eyal Hayden
Gianluca GaidanoGianluca Gaidano
Gianluca Gaidano
Mario PirisiMario Pirisi
Mario Pirisi
PSPier Paolo Sainaghi
Pier Paolo Sainaghi
Introduction. The clinical course of Coronavirus Disease 2019 (COVID-19) is highly heterogenous, ranging from asymptomatic to fatal forms. The identification of clinical and laboratory predictors of poor prognosis may assist clinicians in monitoring strategies and therapeutic decisions. Materials and Methods. In this study, we retrospectively assessed the prognostic value of a simple tool, the complete blood count, on a cohort of 664 patients ( 260; 39%, median age 70 (56-81) years) hospitalized for COVID-19 in Northern Italy. We collected demographic data along with complete blood cell count; moreover, the outcome of the hospital in-stay was recorded. Results. At data cut-off, 221/664 patients (33.3%) had died and 453/664 (66.7%) had been discharged. Red cell distribution width (RDW) ( 10.4; ), neutrophil-to-lymphocyte (NL) ratio ( 7.6; ), and platelet count ( 5.39; ), along with age ( 87.6; ) and gender ( 17.3; ), accurately predicted in-hospital mortality. Hemoglobin levels were not associated with mortality. We also identified the best cut-off for mortality prediction: a was characterized by an odds ratio for in-hospital (2.40-4.82), while the OR for a

26 March 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
Lucio BoglioneLucio Boglione
Lucio Boglione
SPS. Mornese Pinna
S. Mornese Pinna
ANAmedeo De Nicolò
Amedeo De Nicolò
JCJ. Cusato
J. Cusato
GCG. Cariti
G. Cariti
ADA. D'Avolio
A. D'Avolio

24 July 2014 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
Lucio BoglioneLucio Boglione
Lucio Boglione
Jessica CusatoJessica Cusato
Jessica Cusato
ANAmedeo De Nicolò
Amedeo De Nicolò
GCG. Cariti
G. Cariti
GPG. Di Perri
G. Di Perri
ADA. D'AVolio
A. D'AVolio

Verified
Journal Article
Open access
PDF file
FRFrancesco Giuseppe De Rosa
Francesco Giuseppe De Rosa
APAnnagloria Palazzo
Annagloria Palazzo
TRTiziana Rosso
Tiziana Rosso
Nour ShbakloNour Shbaklo
Nour Shbaklo
MMMarco Mussa
Marco Mussa
Silvia CorcioneSilvia Corcione
Silvia Corcione
Background: CORACLE is a retrospective and prospective, regional multicenter registry, developed to evaluate risk factors for mortality in a cohort of patients admitted with SARS-CoV-2 infection within non-intensive wards. Methods: The primary objective was to estimate the role of several prognostic factors on hospital mortality in terms of adjusted Odds Ratios (aOR) with multivariable logistic regression models. Results: A total of 1538 patients were enrolled; 42% were female, and 58% were >70 years old. Deceased patients were 422 (27%), with a median age of 83 years (IQR (Inter Quartile Range) 76–87). Older age at admission (aOR 1.07 per year, 95%CI 1.06–1.09), diabetes (1.41, 1.02–1.94), cardiovascular disease (1.79, 1.31–2.44), immunosuppression (1.65, 1.04–2.62), estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (3.53, 2.26–5.51), higher C-reactive protein values and a decreased PaO2/FiO2 ratio at admission were associated with a higher risk of hospital mortality. Amongst patients still alive on day 7, only hydroxychloroquine (HCQ) treatment was associated with reduced mortality (0.57, 0.36–0.90). Conclusions: Several risk factors were associated with mortality in SARS-CoV-2 positive patients. Although HCQ seems to be the only factor significantly associated with reduced mortality, this result is in contrast with evidence from randomized studies. These results should be interpreted in light of the study limitations.